05 January 2017

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that CSD500, its novel erectogenic condom, has launched in Saudi Arabia by Kabey Pharmaceuticals ("Kabey"), the Company's distribution partner for key territories in the Middle East and North Africa ("MENA"). Kabey anticipates further launches within MENA during 2017.

The launch of the product, under the brand name Futura Max Manex® Super, follows positive feedback from urologists after their trial use of the product. In addition to raising further medical awareness of the product with urologists, Kabey will now implement a direct retail marketing campaign. The marketing plans do not include online sales as, in the MENA region, this is not a popular route to market for such products.

James Barder, Futura's Chief Executive, commented: "We are delighted that our novel erectogenic condom, CSD500, has now been launched in Saudi Arabia by our commercial partner in the Middle East and North Africa, Kabey Pharmaceuticals. The product launch follows positive feedback from urologists after their trial use of CSD500.

"Kabey is well-established with a strong presence in the MENA region. It will now implement a direct retail marketing campaign which we are confident will be successful for CSD500. We look forward to updating the market regarding further launches of CSD500 within MENA during 2017."

This announcement contains inside information.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com